The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
Open Access
- 3 August 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 15 (10), 1156-1166
- https://doi.org/10.1016/s1473-3099(15)00154-1
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- A Recombinant Vesicular Stomatitis Virus Ebola VaccineThe New England Journal of Medicine, 2017
- Phase 1 Trials of rVSV Ebola Vaccine in Africa and EuropeThe New England Journal of Medicine, 2016
- Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman PrimatesPLoS Neglected Tropical Diseases, 2012
- Recombinant Vesicular Stomatitis Virus–Based Vaccines Against Ebola and Marburg Virus InfectionsThe Journal of Infectious Diseases, 2011
- Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola VirusJournal of Virology, 2009
- Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune ResponsesPLOS ONE, 2009
- Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman PrimatesPLoS Pathogens, 2008
- Assessment of a Vesicular Stomatitis Virus–Based Vaccine by Use of the Mouse Model of Ebola Virus Hemorrhagic FeverThe Journal of Infectious Diseases, 2007
- A macrophage marker, siglec‐1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type i interferons and toll‐like receptor agonistsArthritis & Rheumatism, 2007
- Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg virusesNature Medicine, 2005